| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -42,824 | -45,475 |
| Proceeds from sale of technology and other assets | 1,000 | 1,000 |
| Proceeds from maturities of marketable securities | 83,812 | 73,662 |
| Purchase of marketable securities | 54,069 | 46,456 |
| Net cash provided by investing activities | 30,743 | 28,206 |
| Proceeds from exercise of stock options | 0 | 0 |
| Proceeds from issuance of common stock under the 2020 employee share purchase plan | 109 | 79 |
| Net cash provided by financing activities | 109 | 79 |
| Effect of exchange rate fluctuations on cash held | 80 | 129 |
| Net decrease in cash and cash equivalents | -11,892 | -17,061 |
| Cash and cash equivalents at beginning of period | 84,717 | - |
| Cash and cash equivalents at end of period | 72,825 | - |
Repare Therapeutics Inc. (RPTX)
Repare Therapeutics Inc. (RPTX)